Medical Oncology, Wake Forest University School of Medicine, Winston-Salem.
Int J Womens Health. 2010 Aug 24;2:291-4. doi: 10.2147/IJWH.S12335.
In breast cancer survivors, we aimed to describe the frequency of hot flashes and night sweats, frequency and type of treatment, and the association of hot flashes and use of calcium supplements.
Charts of breast cancer survivors were reviewed for information about hot flashes, treatment for hot flashes, and calcium supplementation. Associations between variables were explored using the Chi-square test and Fisher's Exact test.
Eighty-six charts were reviewed. Mean age of the women was 58 years and 79% were postmenopausal. Forty-two (49%) of women had hot flashes and 18 (21%) had night sweats. Thirty-one (36%) were treated for hot flashes. Treatment included selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (n = 19), clonidine (n = 7), Bellergal-S(®) (n = 8), sleep-aid (n = 7), and other (n = 5). Calcium supplementation was recorded in 31%. Of women with hot flashes, 44% took calcium supplements; of women without hot flashes, 18% took calcium supplements (Chi-square P = 0.02).
Hot flashes were recorded in 49% of this group of primarily postmenopausal breast cancer survivors. Women with hot flashes were more likely to be taking calcium supplements. Further exploration of the association between hot flashes and calcium supplementation is warranted.
本研究旨在描述乳腺癌幸存者中热潮汗和盗汗的发生频率、治疗频率和类型，以及热潮汗与钙补充剂使用之间的关系。
对乳腺癌幸存者的病历进行回顾，以获取有关热潮汗、热潮汗治疗和钙补充剂的信息。使用卡方检验和 Fisher 精确检验探索变量之间的关联。
共回顾了 86 份病历。女性的平均年龄为 58 岁，79%处于绝经后状态。42 名（49%）女性有热潮汗，18 名（21%）有盗汗。31 名（36%）接受了热潮汗治疗。治疗包括选择性 5-羟色胺再摄取抑制剂/5-羟色胺-去甲肾上腺素再摄取抑制剂（n=19）、可乐定（n=7）、Bellerga-S（®）（n=8）、助眠药（n=7）和其他（n=5）。记录了 31%的钙补充剂使用情况。有热潮汗的女性中，44%服用了钙补充剂；没有热潮汗的女性中，18%服用了钙补充剂（卡方检验 P=0.02）。
在这组主要为绝经后乳腺癌幸存者中，有 49%记录到热潮汗。有热潮汗的女性更有可能服用钙补充剂。有必要进一步探讨热潮汗与钙补充剂之间的关系。
